The Botticelli investigators are given in the Appendix.
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
Version of Record online: 6 JUN 2008
© 2008 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis
Volume 6, Issue 8, pages 1313–1318, August 2008
How to Cite
ON BEHALF OF THE BOTTICELLI INVESTIGATORS, THE WRITING COMMITTEE, BULLER, H., DEITCHMAN, D., PRINS, M. and SEGERS, A. (2008), Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis, 6: 1313–1318. doi: 10.1111/j.1538-7836.2008.03054.x
- Issue online: 17 JUL 2008
- Version of Record online: 6 JUN 2008
- Received 24 April 2008, accepted 23 May 2008
- 6The Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2: 47–53.